Edwards Lifesciences 미래 성장
Future 기준 확인 1/6
Edwards Lifesciences (는) 각각 연간 1.9% 및 4.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 2.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 23.1% 로 예상됩니다.
주요 정보
1.9%
수익 성장률
2.9%
EPS 성장률
Medical Equipment 수익 성장 | 17.1% |
매출 성장률 | 4.8% |
향후 자기자본 수익률 | 23.1% |
애널리스트 커버리지 | Good |
마지막 업데이트 | 04 Nov 2024 |
최근 미래 성장 업데이트
Recent updates
Estimating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Nov 11Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts
Oct 25Bearish: Analysts Just Cut Their Edwards Lifesciences Corporation (NYSE:EW) Revenue and EPS estimates
Sep 11Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
Aug 30Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Aug 17Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Jul 26Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Jul 26Why Investors Shouldn't Be Surprised By Edwards Lifesciences Corporation's (NYSE:EW) P/E
Jul 12Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jun 24Edwards Lifesciences Corp Looks Bullish (Technical Analysis)
Jun 22Capital Investments At Edwards Lifesciences (NYSE:EW) Point To A Promising Future
May 13Edwards Lifesciences: EPS Acceleration, Shares Poised To Rally (Rating Upgrade)
May 09When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21수익 및 매출 성장 예측
날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
---|---|---|---|---|---|
12/31/2026 | 6,540 | 1,603 | 1,526 | 1,773 | 26 |
12/31/2025 | 5,926 | 1,493 | 1,435 | 1,835 | 30 |
12/31/2024 | 5,837 | 1,387 | 1,415 | 1,922 | 30 |
9/30/2024 | 6,315 | 1,567 | 490 | 806 | N/A |
6/30/2024 | 6,204 | 1,540 | 552 | 866 | N/A |
3/31/2024 | 6,114 | 1,428 | 251 | 528 | N/A |
12/31/2023 | 6,005 | 1,402 | 630 | 896 | N/A |
9/30/2023 | 5,092 | 1,288 | 775 | 1,042 | N/A |
6/30/2023 | 5,168 | 1,296 | 669 | 940 | N/A |
3/31/2023 | 5,279 | 1,451 | 972 | 1,239 | N/A |
12/31/2022 | 5,382 | 1,522 | 953 | 1,218 | N/A |
9/30/2022 | 5,364 | 1,459 | 1,040 | 1,309 | N/A |
6/30/2022 | 5,355 | 1,455 | 1,261 | 1,531 | N/A |
3/31/2022 | 5,357 | 1,539 | 1,428 | 1,725 | N/A |
12/31/2021 | 5,233 | 1,503 | 1,402 | 1,732 | N/A |
9/30/2021 | 5,095 | 1,477 | 1,409 | 1,758 | N/A |
6/30/2021 | 4,925 | 1,462 | 1,050 | 1,443 | N/A |
3/31/2021 | 4,474 | 851 | 717 | 1,148 | N/A |
12/31/2020 | 4,386 | 823 | 647 | 1,054 | N/A |
9/30/2020 | 4,369 | 794 | 692 | 1,057 | N/A |
6/30/2020 | 4,322 | 744 | 941 | 1,279 | N/A |
3/31/2020 | 4,484 | 1,108 | 1,087 | 1,389 | N/A |
12/31/2019 | 4,348 | 1,047 | 905 | 1,183 | N/A |
9/30/2019 | 4,152 | 774 | 809 | 1,073 | N/A |
6/30/2019 | 3,964 | 725 | 705 | 978 | N/A |
3/31/2019 | 3,821 | 765 | 523 | 777 | N/A |
12/31/2018 | 3,723 | 722 | 685 | 927 | N/A |
9/30/2018 | 3,634 | 712 | 754 | 998 | N/A |
6/30/2018 | 3,549 | 657 | N/A | 966 | N/A |
3/31/2018 | 3,447 | 560 | N/A | 1,024 | N/A |
12/31/2017 | 3,435 | 584 | N/A | 1,001 | N/A |
9/30/2017 | 3,315 | 745 | N/A | 838 | N/A |
6/30/2017 | 3,232 | 716 | N/A | 733 | N/A |
3/31/2017 | 3,150 | 657 | N/A | 726 | N/A |
12/31/2016 | 2,964 | 570 | N/A | 704 | N/A |
9/30/2016 | 2,867 | 552 | N/A | 607 | N/A |
6/30/2016 | 2,743 | 528 | N/A | 604 | N/A |
3/31/2016 | 2,601 | 515 | N/A | 584 | N/A |
12/31/2015 | 2,494 | 495 | N/A | 550 | N/A |
9/30/2015 | 2,441 | 463 | N/A | 539 | N/A |
6/30/2015 | 2,433 | 440 | N/A | 349 | N/A |
3/31/2015 | 2,391 | 874 | N/A | 957 | N/A |
12/31/2014 | 2,323 | 811 | N/A | 1,022 | N/A |
9/30/2014 | 2,241 | 777 | N/A | 1,040 | N/A |
6/30/2014 | 2,129 | 759 | N/A | 1,160 | N/A |
3/31/2014 | 2,071 | 306 | N/A | 511 | N/A |
12/31/2013 | 2,046 | 389 | N/A | 473 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: EW 의 연간 예상 수익 증가율( 1.9% )이 saving rate( 2.6% 미만입니다. ).
수익 vs 시장: EW 의 연간 수익( 1.9% ) US 시장( 15.3% 보다 느리게 성장할 것으로 예상됩니다. 15.3% 연간).
고성장 수익: EW 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: EW 의 수익(연간 4.8% ) US 시장( 8.9% 보다 느리게 성장할 것으로 예상됩니다. 8.9% 연간).
고성장 수익: EW 의 수익(연간 4.8% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: EW 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 23.1 %)